Attralus lands $116m Series B
Attralus, Inc., a clinical stage biopharmaceutical company, has secured $116 million in Series B financing.
Attralus, Inc., a clinical stage biopharmaceutical company, has secured $116 million in Series B financing.
Copyright PEI Media
Not for publication, email or dissemination